Results 201 to 210 of about 14,209 (224)

Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis. [PDF]

Int J Mol Sci
Aimo A, Ferrari Chen YF, Chianca M, Mori F, Pucci A, Castiglione V, Musetti V, Caponi L, Fabiani I, Vergaro G, Franzini M, Emdin M, Cardinale D.   +12 more
europepmc   +1 more source

Identifying the quantity profiles of amyloid signature proteins in different types of renal amyloidosis. [PDF]

BMC Nephrol
Wang S, Li D, Zhang X, Zhou F, Wang S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunoglobulin light chain amyloidosis

Expert Review of Hematology, 2013
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage.
MERLINI, GIAMPAOLO, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA   +4 more
openaire   +4 more sources

Treatment of immunoglobulin light chain amyloidosis

Current Hematologic Malignancy Reports, 2009
No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients.
Steven R. Zeldenrust, Morie A. Gertz
openaire   +3 more sources

Free Light Chains of Immunoglobulins in Amyloidosis

Acta Medica Scandinavica, 1979
ABSTRACT Monomeric (M) and dimeric (D) forms of free light chains in serum have been measured by a sensitive radioimmunoassay in eight patients with amyloidosis without monoclonal proteins. Significantly elevated concentrations of D lambda chains were demonstrated in two of four patients with localized amyloidosis.
K Sølling, J Sølling
openaire   +3 more sources

Immunoglobulin Light Chain Systemic Amyloidosis

2016
Immunoglobulin light chain amyloidosis (AL) is a rare, complex disease caused by misfolded free light chains produced by a usually small, indolent plasma cell clone. Effective treatments exist that can alter the natural history, provided that they are started before irreversible organ damage has occurred.
Angela Dispenzieri, Giampaolo Merlini
openaire   +3 more sources

Glycosylation of immunoglobulin light chains associated with amyloidosis

Amyloid, 2000
AL amyloidosis is a fatal disease caused by deposition of immunoglobulin light chains in a fibrillarforin (AL) in various organs. By searching the Kabat database of immunoglobulin sequences using the KabatMan software, we have shown that there is a preponderance of the consensus glycosylation sequon (AsnXxxSer/Thr) in the framework regions of amyloid ...
Knut Sletten, Gunnar Husby, David Bailey, David V. Renouf, L. A. Omtvedt, Svein Haavik, Nikolay A. Paramonov, Elizabeth F. Hounsell, Michael J. Davies   +8 more
openaire   +3 more sources

[Treatment strategy for immunoglobulin light chain amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2021
Systemic AL amyloidosis is a disease wherein amyloid proteins derived from monoclonal immunoglobulin light chains produced by abnormal plasma cells are deposited in the tissues through the whole body and cause organ failure. The treatment aims to minimize treatment-related toxicity and mortality to achieve a deeper and more persistent hematologic ...
openaire   +2 more sources

Systemic Immunoglobulin Light-Chain Amyloidosis

Clinical Lymphoma and Myeloma, 2006
Amyloidosis is a rare disease in which amyloid fibrils compromise organ function and lead to death. Systemic immunoglobulin light-chain amyloidosis, usually caused by free light chains (FLCs) made by clonal plasma cells, is the most frequent type. Hereditary and senile systemic amyloidosis are less frequent types.
openaire   +3 more sources

Therapy for immunoglobulin light chain amyloidosis: the new and the old

Blood Reviews, 2004
An accurate diagnosis of amyloidosis and its subtype classification are essential for disease prognostication and treatment. In primary amyloidosis, overall median survival is approximately 2 years and may be less in patients with cardiomyopathy. Current therapy for primary amyloidosis is suboptimal.
Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz   +2 more
openaire   +3 more sources